LakePharma and NJ Bio partner on ‘one-stop’ ADC manufacturing service

By Vassia Barba

- Last updated on GMT

(Image: Getty/extender01)
(Image: Getty/extender01)

Related tags Antibody drug conjugates antibody-drug conjugates Antibody Contract manufacturing

Antibody-focused service providers merge their offerings to create a ‘seamless workflow’ on antibody-drug conjugates to help save developers’ time and costs.

LakePharma, a US-based biologics contract research, development, and manufacturing organization (CRDMO), will work jointly with NJ Biopharmaceuticals, a provider of chemistry and biology services, to create a streamlined antibody-drug conjugate (ADC) development service.

Specifically, the agreement will see LakePharma manufacture and provide antibodies as starting materials for ADC development, which will be carried out by NJ Bio, in order to support drug developers working on such treatments.

This joint service, leveraging the capabilities of both companies in their field, is expected to create a ‘seamless workflow’ for clients, from initial antibody discovery to the production of the drug conjugates in a manner “significantly more efficient both in time and expense,”​ LakePharma stated.

Commenting on the partnership, Nareshkumar Jain, CEO of NJ Bio, stated that the partnership will expand and add value to the ADC services that the companies currently provide, creating cost-effective solutions through the provision of complementary service offerings.

The therapeutic potential of ADCs and their uptake from the industry has seen several companies establishing partnerships, such as AstraZeneca with Daiichi Sankyo​ last year, as well as investment in capabilities, such as that of Lonza​ – which stated that it was preparing for a ‘new wave’ of ADC therapies.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars